What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

Omali Pitiyarachchi; Michael Friedlander; James J. Java; John K. Chan; Deborah K. Armstrong; Maurie Markman; Thomas J. Herzog; Bradley J. Monk; Floor Backes; Angeles Alvarez Secord; Albert Bonebrake; Peter G. Rose; Krishnansu S. Tewari; Samuel S. Lentz; Melissa A. Geller; Larry J. Copeland; Robert S. Mannel

doi:10.1016/j.ygyno.2022.07.004

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

Omali Pitiyarachchi
, Michael Friedlander
, James J. Java
, John K. Chan
, Deborah K. Armstrong
, Maurie Markman
, Thomas J. Herzog
, Bradley J. Monk
, Floor Backes
, Angeles Alvarez Secord
, Albert Bonebrake
, Peter G. Rose
, Krishnansu S. Tewari
, Samuel S. Lentz
, Melissa A. Geller
, Larry J. Copeland
, Robert S. Mannel

Obstetrics, Gynecology and Women's Health - Gynecologic Oncology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS.

METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS.

RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis.

CONCLUSIONS: Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.

Original language	English (US)
Pages (from-to)	410-416
Number of pages	7
Journal	Gynecologic oncology
Volume	166
Issue number	3
DOIs	https://doi.org/10.1016/j.ygyno.2022.07.004
State	Published - Sep 2022

Bibliographical note

Funding Information:
MF reports honoraria from Astra Zeneca;GSK;Novartis;MSD;Takeda;Lilly;Eisei for advisory boards/consulting.Speaker fees from Astra Zeneca;GSK and MSD. Institutional research funding from Astra Zeneca;Novartis and Beigene. Travel expenses for Astra Zeneca.

Funding Information:
MF supported by NHMRC Program Grant APP1092856 .

Publisher Copyright:
© 2022 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

10-year survival
Advanced ovarian cancer
Chemotherapy
Cancer Survivors
Humans
Middle Aged
Randomized Controlled Trials as Topic
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Disease-Free Survival
Ovarian Neoplasms/drug therapy
Carcinoma, Ovarian Epithelial/drug therapy
Female
Neoplasm Staging

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Journal Article

Publisher link

10.1016/j.ygyno.2022.07.004

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer'. Together they form a unique fingerprint.

Cite this

Pitiyarachchi, O., Friedlander, M., Java, J. J., Chan, J. K., Armstrong, D. K., Markman, M., Herzog, T. J., Monk, B. J., Backes, F., Secord, A. A., Bonebrake, A., Rose, P. G., Tewari, K. S., Lentz, S. S., Geller, M. A., Copeland, L. J., & Mannel, R. S. (2022). What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecologic oncology, 166(3), 410-416. https://doi.org/10.1016/j.ygyno.2022.07.004

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. / Pitiyarachchi, Omali; Friedlander, Michael; Java, James J. et al.
In: Gynecologic oncology, Vol. 166, No. 3, 09.2022, p. 410-416.

Research output: Contribution to journal › Article › peer-review

Pitiyarachchi, O, Friedlander, M, Java, JJ, Chan, JK, Armstrong, DK, Markman, M, Herzog, TJ, Monk, BJ, Backes, F, Secord, AA, Bonebrake, A, Rose, PG, Tewari, KS, Lentz, SS, Geller, MA, Copeland, LJ & Mannel, RS 2022, 'What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer', Gynecologic oncology, vol. 166, no. 3, pp. 410-416. https://doi.org/10.1016/j.ygyno.2022.07.004

Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M et al. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecologic oncology. 2022 Sep;166(3):410-416. doi: 10.1016/j.ygyno.2022.07.004

Pitiyarachchi, Omali ; Friedlander, Michael ; Java, James J. et al. / What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. In: Gynecologic oncology. 2022 ; Vol. 166, No. 3. pp. 410-416.

@article{fe527c4c3d3e4f3eaf884dc61f3e1f0e,

title = "What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer",

abstract = "OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS.METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS.RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26\% (95\% CI, 23-28\%) and LTDFS ≥10 years was 18\% (95\% CI, 16-20\%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis.CONCLUSIONS: Approximately 18\% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.",

keywords = "10-year survival, Advanced ovarian cancer, Chemotherapy, Cancer Survivors, Humans, Middle Aged, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Disease-Free Survival, Ovarian Neoplasms/drug therapy, Carcinoma, Ovarian Epithelial/drug therapy, Female, Neoplasm Staging",

author = "Omali Pitiyarachchi and Michael Friedlander and Java, \{James J.\} and Chan, \{John K.\} and Armstrong, \{Deborah K.\} and Maurie Markman and Herzog, \{Thomas J.\} and Monk, \{Bradley J.\} and Floor Backes and Secord, \{Angeles Alvarez\} and Albert Bonebrake and Rose, \{Peter G.\} and Tewari, \{Krishnansu S.\} and Lentz, \{Samuel S.\} and Geller, \{Melissa A.\} and Copeland, \{Larry J.\} and Mannel, \{Robert S.\}",

note = "Funding Information: MF reports honoraria from Astra Zeneca;GSK;Novartis;MSD;Takeda;Lilly;Eisei for advisory boards/consulting.Speaker fees from Astra Zeneca;GSK and MSD. Institutional research funding from Astra Zeneca;Novartis and Beigene. Travel expenses for Astra Zeneca. Funding Information: MF supported by NHMRC Program Grant APP1092856 . Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = sep,

doi = "10.1016/j.ygyno.2022.07.004",

language = "English (US)",

volume = "166",

pages = "410--416",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

AU - Pitiyarachchi, Omali

AU - Friedlander, Michael

AU - Java, James J.

AU - Chan, John K.

AU - Armstrong, Deborah K.

AU - Markman, Maurie

AU - Herzog, Thomas J.

AU - Monk, Bradley J.

AU - Backes, Floor

AU - Secord, Angeles Alvarez

AU - Bonebrake, Albert

AU - Rose, Peter G.

AU - Tewari, Krishnansu S.

AU - Lentz, Samuel S.

AU - Geller, Melissa A.

AU - Copeland, Larry J.

AU - Mannel, Robert S.

N1 - Funding Information: MF reports honoraria from Astra Zeneca;GSK;Novartis;MSD;Takeda;Lilly;Eisei for advisory boards/consulting.Speaker fees from Astra Zeneca;GSK and MSD. Institutional research funding from Astra Zeneca;Novartis and Beigene. Travel expenses for Astra Zeneca. Funding Information: MF supported by NHMRC Program Grant APP1092856 . Publisher Copyright: © 2022 The Authors

PY - 2022/9

Y1 - 2022/9

N2 - OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS.METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS.RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis.CONCLUSIONS: Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.

AB - OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS.METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS.RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis.CONCLUSIONS: Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.

KW - 10-year survival

KW - Advanced ovarian cancer

KW - Chemotherapy

KW - Cancer Survivors

KW - Humans

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Disease-Free Survival

KW - Ovarian Neoplasms/drug therapy

KW - Carcinoma, Ovarian Epithelial/drug therapy

KW - Female

KW - Neoplasm Staging

UR - https://www.scopus.com/pages/publications/85134538631

UR - https://www.scopus.com/pages/publications/85134538631#tab=citedBy

U2 - 10.1016/j.ygyno.2022.07.004

DO - 10.1016/j.ygyno.2022.07.004

M3 - Article

C2 - 35835612

AN - SCOPUS:85134538631

SN - 0090-8258

VL - 166

SP - 410

EP - 416

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 3

ER -

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

Abstract

Bibliographical note

UN SDGs

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this